Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.69 |
| ▸ | CCND1 | P24385 | 15/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.69 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 9/20 | 0.69 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.69 |
| ▸ | CDK2 | P24941 | 9/20 | 0.69 |
| ▸ | CCND2 | P30279 | 7/20 | 0.67 |
| ▸ | CCND3 | P30281 | 7/20 | 0.67 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.67 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.67 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.64 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344501 | 1.00 | CDK4 (0.69) | CDK4CCND1FGFR1CCNA2FGFR2 | |
| SCHEMBL1355312 | 0.91 | CDK4 (0.67) | CDK4CCND1FGFR1CCNA2FGFR2 | |
| SCHEMBL12639361 | 0.88 | CDK4 (0.71) | CDK4CCND1FGFR1CCNA2FGFR2 | |
| SCHEMBL1355413 | 0.88 | CDK4 (0.72) | CDK4CCND1FGFR1CCNA2FGFR2 | |
| SCHEMBL12639296 | 0.88 | CDK4 (0.72) | CDK4CCND1FGFR1CCNA2FGFR2 | |
| SCHEMBL344014 | 0.87 | CDK4 (0.73) | CDK4CCND1FGFR1CCNA2FGFR2 | |
| SCHEMBL1355826 | 0.87 | CDK1 (0.57) | CDK4CCND1FGFR1CCNA2FGFR2 | |
| SCHEMBL1355087 | 0.87 | CDK4 (0.73) | CDK4CCND1FGFR1CCNA2FGFR2 | |
| SCHEMBL12639329 | 0.87 | CDK4 (0.61) | CDK4CCND1FGFR1CCNA2FGFR2 | |
| SCHEMBL344178 | 0.86 | CDK4 (0.71) | CDK4CCND1FGFR1CCNA2FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | CDK4 101/4885CCND1 160/4885FGFR1 940/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | CDK4 101/4885CCND1 160/4885FGFR1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.